Isis Pharma (ISIS) Income Statement

Click line-items for a historical chart and %

Research and development revenue under collaborative agreements
Licensing and royalty revenue
Total revenue	110.93M
Research and development
General and administrative	10.19M
Total operating expenses	94.82M
Loss from operations	16.11M
Equity in net loss of Regulus Therapeutics Inc.
Investment income	989K
Interest expense	-9.75M
Gain (loss) on investments, net
Loss before income tax expense
Income tax expense	0
Net loss	7.35M
Basic net loss (in dollars per share)	0.06
Diluted net loss (in dollars per share)	0.06
Shares used in computing basic net loss per share (in shares)	120.99M
Shares used in computing diluted net loss per share (in shares)	123.38M

Entities mentioned with isis

View All Entities